Prolonged, low dose alpha-tocopherol therapy counteracts intercellular cell adhesion molecule-1 activation.
Détails
ID Serval
serval:BIB_1F4C49CFA628
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Prolonged, low dose alpha-tocopherol therapy counteracts intercellular cell adhesion molecule-1 activation.
Périodique
Clinica chimica acta; international journal of clinical chemistry
ISSN
0009-8981 (Print)
ISSN-L
0009-8981
Statut éditorial
Publié
Date de publication
06/2002
Peer-reviewed
Oui
Volume
320
Numéro
1-2
Pages
5-9
Langue
anglais
Notes
Publication types: Clinical Trial ; Comparative Study ; Journal Article ; Randomized Controlled Trial
Publication Status: ppublish
Publication Status: ppublish
Résumé
Up-regulation of ICAM-1 at the vascular endothelial level is one of the most important promoters in the slow progression of a healthy vessel to an atherosclerotic one. The current study aimed to evaluate whether low dose of the antioxidant alpha-tocopherol affects the circulating soluble (s) ICAM-1 in healthy subjects.
Either alpha-tocopherol E (50 I.U./day) or placebo was randomly, double-blindly given to 39 healthy male volunteers (mean age 41.6+/-5.9 years) over a period of 20 weeks.
At the baseline, sICAM-1 levels were inversely correlated with alpha-tocopherol concentrations (r=-0.525, p<0.0001). Twenty weeks of alpha-tocopherol supplementation (n=20 subjects) significantly decreased the circulating sICAM-1 levels (from 149.2+/-18.4 to 131.5+/-17.2 microg l(-1), p<0.004) while it increased the alpha-tocopherol concentrations (from 25.8+/-5.0 to 31.2+/-5.7 micromol l(-1), p<0.003). No significant changes in plasma sICAM-1 and alpha-tocopherol levels were observed in placebo-treated subjects (n=19). In actively treated subjects, changes in circulating sICAM-1 were inversely correlated with changes in alpha-tocopherol concentrations (r=-0.597, p=0.005).
Plasma sICAM-1 concentrations are stable in healthy subjects over a period of 20 weeks while they significantly decreased with low dose of alpha-tocopherol. Thus, antioxidant vitamins are likely to counteract with endothelial changes that could potentially trigger the atherogenetic process.
Either alpha-tocopherol E (50 I.U./day) or placebo was randomly, double-blindly given to 39 healthy male volunteers (mean age 41.6+/-5.9 years) over a period of 20 weeks.
At the baseline, sICAM-1 levels were inversely correlated with alpha-tocopherol concentrations (r=-0.525, p<0.0001). Twenty weeks of alpha-tocopherol supplementation (n=20 subjects) significantly decreased the circulating sICAM-1 levels (from 149.2+/-18.4 to 131.5+/-17.2 microg l(-1), p<0.004) while it increased the alpha-tocopherol concentrations (from 25.8+/-5.0 to 31.2+/-5.7 micromol l(-1), p<0.003). No significant changes in plasma sICAM-1 and alpha-tocopherol levels were observed in placebo-treated subjects (n=19). In actively treated subjects, changes in circulating sICAM-1 were inversely correlated with changes in alpha-tocopherol concentrations (r=-0.597, p=0.005).
Plasma sICAM-1 concentrations are stable in healthy subjects over a period of 20 weeks while they significantly decreased with low dose of alpha-tocopherol. Thus, antioxidant vitamins are likely to counteract with endothelial changes that could potentially trigger the atherogenetic process.
Mots-clé
Adult, Arteriosclerosis/etiology, Humans, Intercellular Adhesion Molecule-1/blood, Logistic Models, Male, Middle Aged, alpha-Tocopherol/administration & dosage, alpha-Tocopherol/adverse effects, alpha-Tocopherol/pharmacology
Pubmed
Web of science
Création de la notice
25/08/2017 21:02
Dernière modification de la notice
20/08/2019 12:55